- Home
- BPMC vs ADMA Comparison
BPMC vs ADMA Comparison
Compare BPMC & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPMC
- ADMA
- Stock Information
- Founded
- BPMC 2008
- ADMA 2004
- Country
- BPMC United States
- ADMA United States
- Employees
- BPMC N/A
- ADMA N/A
- Industry
- BPMC Biotechnology: Pharmaceutical Preparations
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BPMC Health Care
- ADMA Health Care
- Exchange
- BPMC Nasdaq
- ADMA Nasdaq
- Market Cap
- BPMC 5.8B
- ADMA 5.1B
- IPO Year
- BPMC 2015
- ADMA N/A
- Fundamental
- Price
- BPMC $101.35
- ADMA $19.84
- Analyst Decision
- BPMC Buy
- ADMA Strong Buy
- Analyst Count
- BPMC 18
- ADMA 4
- Target Price
- BPMC $125.88
- ADMA $24.25
- AVG Volume (30 Days)
- BPMC 789.4K
- ADMA 3.4M
- Earning Date
- BPMC 05-01-2025
- ADMA 05-07-2025
- Dividend Yield
- BPMC N/A
- ADMA N/A
- EPS Growth
- BPMC N/A
- ADMA N/A
- EPS
- BPMC N/A
- ADMA 0.84
- Revenue
- BPMC $562,121,000.00
- ADMA $459,381,000.00
- Revenue This Year
- BPMC $44.49
- ADMA $19.45
- Revenue Next Year
- BPMC $33.04
- ADMA $28.10
- P/E Ratio
- BPMC N/A
- ADMA $23.74
- Revenue Growth
- BPMC 99.19
- ADMA 62.23
- 52 Week Low
- BPMC $73.04
- ADMA $9.40
- 52 Week High
- BPMC $121.90
- ADMA $25.67
- Technical
- Relative Strength Index (RSI)
- BPMC 56.34
- ADMA 45.08
- Support Level
- BPMC $94.38
- ADMA $18.95
- Resistance Level
- BPMC $102.52
- ADMA $20.14
- Average True Range (ATR)
- BPMC 3.77
- ADMA 0.78
- MACD
- BPMC -0.38
- ADMA -0.13
- Stochastic Oscillator
- BPMC 79.29
- ADMA 47.59
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.